Wo geht´s hin - mit BIOSITE ? - 500 Beiträge pro Seite
eröffnet am 15.05.04 17:24:15 von
neuester Beitrag 21.12.04 10:36:29 von
neuester Beitrag 21.12.04 10:36:29 von
Beiträge: 7
ID: 860.435
ID: 860.435
Aufrufe heute: 0
Gesamt: 295
Gesamt: 295
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 50 Minuten | 4323 | |
| vor 1 Stunde | 3400 | |
| heute 19:15 | 1931 | |
| vor 1 Stunde | 1906 | |
| vor 51 Minuten | 1815 | |
| 01.05.24, 18:36 | 1695 | |
| vor 1 Stunde | 1668 | |
| vor 1 Stunde | 1516 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.001,60 | +0,59 | 240 | |||
| 2. | 2. | 181,19 | +0,66 | 87 | |||
| 3. | 3. | 9,7000 | +12,27 | 75 | |||
| 4. | 14. | 6,1400 | -1,35 | 69 | |||
| 5. | 11. | 0,1865 | 0,00 | 52 | |||
| 6. | 7. | 0,8750 | -12,50 | 47 | |||
| 7. | 12. | 0,1561 | +2,97 | 38 | |||
| 8. | 6. | 2.302,50 | 0,00 | 36 |
Feedback
Holt nun dieses Papier nur etwas Luft zum weiteren Anstieg
oder??? Was sagen Charttechniker dazu?
oder??? Was sagen Charttechniker dazu?
Kommt noch ein Sprung?
40 Euro?
40 Euro?
30 free trades at Ameritrade.
If you have questions or comments about this topic, check out our message boards.
Biosite 2Q Net Jumps 39%; Co Boosts Yr Views >BSTE
07-29-04 06:39 PM EST
SAN DIEGO (Dow Jones)--Biosite Inc.`s (BSTE) second-quarter net income jumped 39% on strong product sales and contract revenue, prompting the company to raise its full-year revenue and earnings targets.
The revised guidance is now above Wall Street`s expectations.
In a press release Thursday, the maker of diagnostic products said its second- quarter earnings surged to $9.98 million from $7.2 million a year earlier. Earnings per share matched Thomson First Call`s analyst projection and rose to 59 cents a share from 43 cents a share last year.
Total revenue for the period, led by Triage BNP sales, soared 34% to $59.9 million from $44.7 million a year prior. Biosite`s Triage products are used to diagnose heart diseases.
Biosite raised its full-year earnings per share growth target to a range of 43% to 53% over last year`s profit of $1.50 a share, which suggests 2004 earnings of about $2.15 to $2.30 a share. The new outlook exceeds the current Street estimate of $2.14 a share.
The company`s previous earnings growth target range was 25% to 30%.
Based in part on a strong first six months, the company boosted its full-year revenue growth target to between 35% to 40% from its prior forecast of 25% to 30%. The revised guidance would put 2004 revenue at about $233.8 million to $ 242.5 million, compared with $173.2 million in 2003, and above a projected revenue of $230.9 million by nine analysts.
Biosite Inc. - San Diego
2nd Quar June 30:
2004 2003
Revenue $59,862,000 $44,698,000
Net income 9,976,000 7,202,000
Avg shrs (diluted) 16,880,000 16,694,000
Shr earns
Net income .59 .43
-Judy Lam; Dow Jones Newswires; 201-938-5400; AskNewswires@dowjones.com
Dow Jones Newswires
If you have questions or comments about this topic, check out our message boards.
Biosite 2Q Net Jumps 39%; Co Boosts Yr Views >BSTE
07-29-04 06:39 PM EST
SAN DIEGO (Dow Jones)--Biosite Inc.`s (BSTE) second-quarter net income jumped 39% on strong product sales and contract revenue, prompting the company to raise its full-year revenue and earnings targets.
The revised guidance is now above Wall Street`s expectations.
In a press release Thursday, the maker of diagnostic products said its second- quarter earnings surged to $9.98 million from $7.2 million a year earlier. Earnings per share matched Thomson First Call`s analyst projection and rose to 59 cents a share from 43 cents a share last year.
Total revenue for the period, led by Triage BNP sales, soared 34% to $59.9 million from $44.7 million a year prior. Biosite`s Triage products are used to diagnose heart diseases.
Biosite raised its full-year earnings per share growth target to a range of 43% to 53% over last year`s profit of $1.50 a share, which suggests 2004 earnings of about $2.15 to $2.30 a share. The new outlook exceeds the current Street estimate of $2.14 a share.
The company`s previous earnings growth target range was 25% to 30%.
Based in part on a strong first six months, the company boosted its full-year revenue growth target to between 35% to 40% from its prior forecast of 25% to 30%. The revised guidance would put 2004 revenue at about $233.8 million to $ 242.5 million, compared with $173.2 million in 2003, and above a projected revenue of $230.9 million by nine analysts.
Biosite Inc. - San Diego
2nd Quar June 30:
2004 2003
Revenue $59,862,000 $44,698,000
Net income 9,976,000 7,202,000
Avg shrs (diluted) 16,880,000 16,694,000
Shr earns
Net income .59 .43
-Judy Lam; Dow Jones Newswires; 201-938-5400; AskNewswires@dowjones.com
Dow Jones Newswires
Ist ein gutes Papier - aber anscheinend gibt es hier keine
Nachfrage.
Nachfrage.
Trading Spotlight
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 117 | ||
| 75 | ||
| 45 | ||
| 28 | ||
| 22 | ||
| 22 | ||
| 17 | ||
| 16 | ||
| 15 | ||
| 14 |
